FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308685422> ?p ?o ?g. }

• W4308685422 endingPage "9973" @default.
• W4308685422 startingPage "9963" @default.
• W4308685422 abstract "There are no recommended treatments for chemotherapy-induced peripheral neuropathy (CIPN) prevention. Recruitment to CIPN prevention clinical trials is challenging because it is difficult to enroll patients between the time of cancer diagnosis and the initiation of neurotoxic chemotherapy. The purpose of this exploratory-sequential mixed-methods study was to determine patients' preferences that could affect the choice to participate in CIPN prevention clinical trials.First, twenty cognitive interviews were conducted with adults who completed less than three neurotoxic chemotherapy infusions to clarify clinical trial attributes and levels thought to be important to patients when deciding whether to enroll in CIPN prevention trials (i.e., type of treatment, clinical tests, reimbursement, survey delivery; length of visits, timing of follow-up, when to begin treatment). Second, another eighty-eight patients completed an adaptive choice-based conjoint analysis survey that incorporated the finalized attributes and levels. Each level was assigned a part-worth utility score using Hierarchical Bayes Estimation. The relative importance of each attribute was calculated.The attributes with the highest relative importance values were type of treatment (27.1%) and length of study visits (20.2%). The preferred levels included non-medicine treatment (53.49%), beginning treatment after experiencing CIPN (60.47%), email surveys (63.95%), assessments that include surveys and clinical exams (39.53%), under 30-min visits (44.19%), $50/week reimbursement (39.53%), and 1-month post-chemotherapy follow-up visits (32.56%).Patients' preferences for participation may be included in the design of future CIPN prevention clinical trials to potentially bolster study enrollment." @default.
• W4308685422 created "2022-11-14" @default.
• W4308685422 creator A5008397526 @default.
• W4308685422 creator A5010632532 @default.
• W4308685422 creator A5022028044 @default.
• W4308685422 creator A5027170448 @default.
• W4308685422 creator A5031649042 @default.
• W4308685422 creator A5035525748 @default.
• W4308685422 creator A5057013722 @default.
• W4308685422 date "2022-11-10" @default.
• W4308685422 modified "2023-09-26" @default.
• W4308685422 title "Identifying participants’ preferences for modifiable chemotherapy-induced peripheral neuropathy prevention clinical trial factors: an adaptive choice-based conjoint analysis" @default.
• W4308685422 cites W1680300731 @default.
• W4308685422 cites W1842042263 @default.
• W4308685422 cites W2033166018 @default.
• W4308685422 cites W2035514720 @default.
• W4308685422 cites W2040163808 @default.
• W4308685422 cites W2083329137 @default.
• W4308685422 cites W2099210388 @default.
• W4308685422 cites W2104450747 @default.
• W4308685422 cites W2113464761 @default.
• W4308685422 cites W2121619367 @default.
• W4308685422 cites W2276317048 @default.
• W4308685422 cites W2359816812 @default.
• W4308685422 cites W2466700580 @default.
• W4308685422 cites W2510256705 @default.
• W4308685422 cites W2556340929 @default.
• W4308685422 cites W2571562544 @default.
• W4308685422 cites W2580670726 @default.
• W4308685422 cites W2614049475 @default.
• W4308685422 cites W2626107769 @default.
• W4308685422 cites W2738125829 @default.
• W4308685422 cites W2765144729 @default.
• W4308685422 cites W2773313331 @default.
• W4308685422 cites W2883158730 @default.
• W4308685422 cites W2895879420 @default.
• W4308685422 cites W2947500214 @default.
• W4308685422 cites W3043680095 @default.
• W4308685422 cites W3086070807 @default.
• W4308685422 cites W3124228313 @default.
• W4308685422 cites W3138116475 @default.
• W4308685422 cites W3206757991 @default.
• W4308685422 cites W368098940 @default.
• W4308685422 cites W4200469801 @default.
• W4308685422 cites W2587510724 @default.
• W4308685422 doi "https://doi.org/10.1007/s00520-022-07447-y" @default.
• W4308685422 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36355216" @default.
• W4308685422 hasPublicationYear "2022" @default.
• W4308685422 type Work @default.
• W4308685422 citedByCount "0" @default.
• W4308685422 crossrefType "journal-article" @default.
• W4308685422 hasAuthorship W4308685422A5008397526 @default.
• W4308685422 hasAuthorship W4308685422A5010632532 @default.
• W4308685422 hasAuthorship W4308685422A5022028044 @default.
• W4308685422 hasAuthorship W4308685422A5027170448 @default.
• W4308685422 hasAuthorship W4308685422A5031649042 @default.
• W4308685422 hasAuthorship W4308685422A5035525748 @default.
• W4308685422 hasAuthorship W4308685422A5057013722 @default.
• W4308685422 hasBestOaLocation W43086854221 @default.
• W4308685422 hasConcept C126322002 @default.
• W4308685422 hasConcept C134018914 @default.
• W4308685422 hasConcept C160735492 @default.
• W4308685422 hasConcept C162324750 @default.
• W4308685422 hasConcept C168563851 @default.
• W4308685422 hasConcept C175444787 @default.
• W4308685422 hasConcept C1862650 @default.
• W4308685422 hasConcept C2778054375 @default.
• W4308685422 hasConcept C2779289229 @default.
• W4308685422 hasConcept C2779703844 @default.
• W4308685422 hasConcept C2779901536 @default.
• W4308685422 hasConcept C2781249084 @default.
• W4308685422 hasConcept C50522688 @default.
• W4308685422 hasConcept C535046627 @default.
• W4308685422 hasConcept C555293320 @default.
• W4308685422 hasConcept C71924100 @default.
• W4308685422 hasConceptScore W4308685422C126322002 @default.
• W4308685422 hasConceptScore W4308685422C134018914 @default.
• W4308685422 hasConceptScore W4308685422C160735492 @default.
• W4308685422 hasConceptScore W4308685422C162324750 @default.
• W4308685422 hasConceptScore W4308685422C168563851 @default.
• W4308685422 hasConceptScore W4308685422C175444787 @default.
• W4308685422 hasConceptScore W4308685422C1862650 @default.
• W4308685422 hasConceptScore W4308685422C2778054375 @default.
• W4308685422 hasConceptScore W4308685422C2779289229 @default.
• W4308685422 hasConceptScore W4308685422C2779703844 @default.
• W4308685422 hasConceptScore W4308685422C2779901536 @default.
• W4308685422 hasConceptScore W4308685422C2781249084 @default.
• W4308685422 hasConceptScore W4308685422C50522688 @default.
• W4308685422 hasConceptScore W4308685422C535046627 @default.
• W4308685422 hasConceptScore W4308685422C555293320 @default.
• W4308685422 hasConceptScore W4308685422C71924100 @default.
• W4308685422 hasFunder F4320317230 @default.
• W4308685422 hasFunder F4320337359 @default.
• W4308685422 hasIssue "12" @default.
• W4308685422 hasLocation W43086854221 @default.
• W4308685422 hasLocation W43086854222 @default.
• W4308685422 hasLocation W43086854223 @default.
• W4308685422 hasOpenAccess W4308685422 @default.

• next